Field Trip Health Ltd. - News

2021 2020 2019

09/24/2021

Field Trip Health Announces Voting Results From the Annual General and Special Meeting of Shareholders

09/10/2021

Field Trip Health Ltd. to Participate in Four Investor Conferences in September

09/09/2021

Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104

08/31/2021

Field Trip Health Ltd. Announces Launch Of “Kap Co-Operative” Program, Enabling Independent Psychedelic Therapists To Practice At Its Field Trip Health Centers; Also Launches Training Programs To Educate A New Generation Of Psychedelic Clinicians

08/16/2021

Field Trip Health Ltd. Reports Fiscal First Quarter 2022 Financial Results

08/10/2021

Field Trip Health Ltd. Schedules First Fiscal Quarter 2022 Financial Results Conference Call for Tuesday, August 17, 2021 at 8:30 am ET

07/27/2021

Field Trip Health Ltd. to Commence Trading on the NASDAQ on July 29, 2021 Under the Symbol FTRP

07/23/2021

Field Trip Health Ltd. Obtains Conditional Approval to List on Nasdaq Under the Symbol "FTRP"

07/08/2021

Field Trip Health Ltd. to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

06/24/2021

Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results

06/17/2021

Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year 2021 Financial Results Conference Call for Friday, June 25, 2021 At 8:00 am ET

06/15/2021

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound

06/08/2021

Field Trip Health Ltd. Applies to List Its Common Shares on the NASDAQ Stock Market

06/03/2021

Field Trip Health Ltd. to Commence Trading on the Toronto Stock Exchange on June 7, 2021

05/27/2021

Field Trip Health Ltd. Receives Conditional Approval to Up-List to the Toronto Stock Exchange

05/20/2021

Former Senate Majority Leader Tom Daschle Appointed Special Adviser to Field Trip Health Ltd.

05/18/2021

Canadians Are Not OK, 83% of Canadians Report One Or More Symptoms of Depression With Many Turning To Substances To Cope With Negative Emotions During COVID-19 Pandemic, According to Field Trip Health's First Annual "State of Mind" Survey

05/18/2021

More than 80% of Americans report one or more symptoms of depression, and many have turned to substances to cope with negative emotions during COVID-19 Pandemic, according to Field Trip Health’s First Annual “State of Mind” Survey

05/06/2021

Field Trip Health Ltd. Announces DTC Eligibility

05/04/2021

Field Trip Health Ltd. Announces Opening of Psychedelic-Enhanced Therapy Center in Houston; Locations of Next 5 Field Trip Health Centers

03/17/2021

Field Trip Health Ltd. Announces Closing of $95 Million Bought Deal Financing

02/26/2021

Field Trip Health Announces Upsize to Previously Announced Bought Deal Public Offering

02/25/2021

Field Trip Health Announces $50 Million Bought Deal Offering of Common Shares

02/16/2021

Field Trip Health Ltd. Reports Third Fiscal Quarter 2021 Financial Results

02/10/2021

Field Trip Health Ltd. Schedules Third Fiscal Quarter 2021 Financial Results Conference Call for Wednesday, February 17, 2021 at 8:00 am ET

02/09/2021

Field Trip Health Ltd. Announces Official Opening of Psychedelic Research and Cultivation Facility in Jamaica

01/28/2021

Field Trip Health Ltd. Common Shares to Trade on the OTCQX Best Market

01/26/2021

Field Trip Health Ltd. Announces Opening of Field Trip Health Center in Atlanta, GA, as it Continues Expansion in the US

01/07/2021

Field Trip Health Ltd. Announces Participation in a MAPS-sponsored Multi-Site Study of MDMA-Assisted Therapy to Treat Eating Disorders

01/05/2021

Field Trip Health Ltd. Announces Closing of Bought Deal Financing